Le Lézard
Classified in: Health
Subjects: TDS, MAT

Dr. Rod J. Rohrich Hosts Special Livestreamed Event for the Annual Dallas Rhinoplasty Meeting


DALLAS, June 16, 2020 /PRNewswire-PRWeb/ -- Following the popular annual Dallas Rhinoplasty Meeting, Dallas rhinoplasty specialist, Dr. Rod J. Rohrich, hosted a special, add-on course on rhinoplasty. Over 500 people from nearly 40 countries registered to attend this one day livestreamed event which included steaming surgical presentations, clinical analysis, interactive live panel discussions, and Q&A sessions focused specifically on rhinoplasty and secondary rhinoplasty.

The global event was livestreamed as a virtual alternative to in-person educational conferences, most of which have been put on hold during the social distancing directives put in place to help control the spread of COVID19.

Key topics at this event included detailed nasal analysis as well as the use of finesse technology in rhinoplasty, considerations in ethnic rhinoplasty, correcting nasal asymmetry and the deviated septum, principles in secondary rhinoplasty, the use of cosmetic fillers in rhinoplasty (known as liquid rhinoplasty), and safety guidelines for rhinoplasty and secondary rhinoplasty surgery.

"This type of virtual, interactive livestream meeting will become a standard for global educational conferences moving forward," says Dr. Rohrich, who serves as Chair of the Dallas Rhinoplasty Meeting. "They allow for people all over the world to learn without leaving home during these challenging times. We are proud to be on the forefront of these technological advances that help bring convenience and safety to our global educational meetings."

About Dr. Rohrich

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential surgeons in this century. He is a Clinical Professor of Plastic Surgery at Baylor College of Medicine and was the Founding Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

Dr. Rohrich also serves as the Editor-in-Chief of the most respected global peer reviewed plastic surgery journal ? the Journal of Plastic and Reconstructive Surgery. He developed and is Editor-in-Chief of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 900 peer reviewed articles and six textbooks in plastic surgery

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America's best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession's highest honors, the Plastic Surgery Educational Foundation Distinguished Service Award, which recognizes his contributions to education in plastic surgery.

 

SOURCE Dr. Rod J. Rohrich


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: